T-Therapeutics

T-Therapeutics is a Cambridge spinout building T-cell engager therapies from fully human T-cell receptors generated in engineered mice. The approach targets proteins inside cells that conventional antibodies cannot reach. A USD 133 million Series B in November takes two lead programmes toward clinical proof of concept.